BEIJING, June 27 (Reuters) - China's National Medical Products Administration has approved domestic drugmaker Innovent Biologics's 1801.HK weight control peptide injection's entry into the market, the regulator said in a statement on Friday.
(Reporting by Beijing Newsroom; Editing by Muralikumar Anantharaman)
((yukun.zhang@thomsonreuters.com;))